KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Interest Expenses (2018 - 2025)

Vertex Pharmaceuticals has reported Interest Expenses over the past 10 years, most recently at $3.3 million for Q4 2025.

  • Quarterly results put Interest Expenses at $3.3 million for Q4 2025, up 17.86% from a year ago — trailing twelve months through Dec 2025 was $13.3 million (down 56.54% YoY), and the annual figure for FY2025 was $13.3 million, down 56.54%.
  • Interest Expenses for Q4 2025 was $3.3 million at Vertex Pharmaceuticals, roughly flat from $3.3 million in the prior quarter.
  • Over the last five years, Interest Expenses for VRTX hit a ceiling of $11.2 million in Q2 2023 and a floor of $2.8 million in Q4 2024.
  • Median Interest Expenses over the past 3 years was $7.5 million (2024), compared with a mean of $7.0 million.
  • Biggest five-year swings in Interest Expenses: plummeted 73.58% in 2024 and later grew 17.86% in 2025.
  • Vertex Pharmaceuticals' Interest Expenses stood at $10.6 million in 2023, then plummeted by 73.58% to $2.8 million in 2024, then increased by 17.86% to $3.3 million in 2025.
  • The last three reported values for Interest Expenses were $3.3 million (Q4 2025), $3.3 million (Q3 2025), and $3.7 million (Q2 2025) per Business Quant data.